We are live on
!
Find out more
FCMI
Foresite Capital Management II Portfolio holdings
AUM
$29.2M
1-Year Est. Return
44.84%
This Fund
S&P 500
This Quarter
Est. Return
+5.43%
1 Year Est. Return
+44.84%
3 Year Est. Return
-66.21%
5 Year Est. Return
-36.36%
10 Year Est. Return
–
AUM
$284M
AUM Growth
-$16.8M
(-5.6%)
Cap. Flow
-$22.2M
Cap. Flow
% of AUM
-7.83%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
12
New
1
Increased
3
Reduced
2
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ADAP
Adaptimmune Therapeutics
ADAP
|
+$3.74M |
| 2 |
AIMT
Aimmune Therapeutics
AIMT
|
+$1.13M |
| 3 |
SGMO
SANGAMO THERAPEUTICS INC
SGMO
|
+$571K |
| 4 |
BDSI
BioDelivery Sciences International, Inc.
BDSI
|
+$72.3K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AERI
Aerie Pharmaceuticals
AERI
|
+$11.6M |
| 2 |
EPZM
Epizyme, Inc
EPZM
|
+$1.4M |
| 3 |
Ardelyx
ARDX
|
+$808K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 33.34% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AERI
1
DELISTED
Aerie Pharmaceuticals
AERI
| $98.9M | 34.86% |
1,464,749
-207,965
| -12% | -$11.6M |
|
|
AIMT
2
DELISTED
Aimmune Therapeutics
AIMT
| $90.3M | 31.8% |
3,356,749
+36,804
| +1% | +$1.13M |
|
|
ALDR
3
DELISTED
Alder Biopharmaceuticals
ALDR
| $26.6M | 9.39% |
1,686,220
| – | – |
|
4
Insmed
INSM
$23.2B
| $22.9M | 8.06% |
967,636
| – | – |
|
|
EPZM
5
DELISTED
Epizyme, Inc
EPZM
| $19.9M | 7.01% |
1,468,215
-89,893
| -6% | -$1.4M |
|
|
XLRN
6
DELISTED
Acceleron Pharma
XLRN
| $11.9M | 4.18% |
244,756
| – | – |
|
|
ADAP
7
DELISTED
Adaptimmune Therapeutics
ADAP
| $8.31M | 2.93% |
700,000
+300,000
| +75% | +$3.74M |
|
8
Denali Therapeutics
DNLI
$3.67B
| $3.81M | 1.34% |
250,000
| – | – |
|
|
SGMO
9
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $1.14M | 0.4% |
80,500
+34,362
| +74% | +$571K |
|
|
BDSI
10
DELISTED
BioDelivery Sciences International, Inc.
BDSI
| $90K | 0.03% |
+30,500
| New | +$72.3K |
|
|
11
Ardelyx
ARDX
$1.24B
| – | – |
-159,967
| Closed | -$808K |
|
|
AIMT
12
PUT
DELISTED
Aimmune Therapeutics
AIMT
| – | – |
-437,900
| Closed | -$13.9M |
|
Similar funds
AG
SAM
AC
QI
TAAM
NAM
MSKCC
BRC
Foresite Capital Management II's Q2 2018 Portfolio in Review
As of Q2 2018, Foresite Capital Management II held 12 positions worth $284M, down 5.6% from $301M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Foresite Capital Management II withdrew a net $22.2M in Q2 2018, closing 2 positions and reducing 2 holdings. Its most notable exit was Ardelyx, an estimated $808K position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 33% of assets, up from 30% a quarter earlier.
Against the trend, Foresite Capital Management II opened a new position in BioDelivery Sciences International, Inc. worth $90K.
- Foresite Capital Management II's largest Q2 2018 buy was BioDelivery Sciences International, Inc.: 30,500 shares worth $90K.
- Foresite Capital Management II added most to Adaptimmune Therapeutics in Q2 2018, an estimated $3.74M increase.
- Foresite Capital Management II's biggest Q2 2018 reduction was Aerie Pharmaceuticals, cutting an estimated $11.6M.
- Foresite Capital Management II fully exited Ardelyx in Q2 2018, selling an estimated $808K.
- Foresite Capital Management II's ten largest holdings make up 100% of its $284M portfolio in Q2 2018.
- Foresite Capital Management II opened 1 new position and closed 2 in Q2 2018.
- Foresite Capital Management II's portfolio value fell 5.6% quarter-over-quarter to $284M.
Based on Foresite Capital Management II's 13F filing for Q2 2018, filed 14 Aug 2018.